Global Osteoarthritis Therapeutics Market
Global Osteoarthritis Therapeutics Market

Osteoarthritis Therapeutics Comprehensive Study by Drug Type (Prescription Drugs, Over-the-Counter Drugs), Route of Administration (Parenteral Route, Topical Route, Oral Route), Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Small Joint Osteoarthritis, Shoulder Osteoarthritis, Other) Players and Region - Global Market Outlook to 2026

Osteoarthritis Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026 | CAGR: 9.05%  

Feb 2021 Edition 235 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Osteoarthritis Therapeutics Market Overview:
Osteoarthritis is a primary cause of pain & disability among adults with a current frequency of ~15% and a predicted prevalence of ~35% by 2030. It can affect any joint, but mostly the knees, hips, lower back and neck and small joints of fingers. It is a chronic (long-term) disease for which there is no cure. As per an estimation, over 30 million adults in the United States have osteoarthritis. Moreover, one in four adults will develop symptoms of hip osteoarthritis by age 85 and one in 12 people aged over 60 have hand osteoarthritis. The use of prescription and over-the-counter medications to reduce pain and decrease inflammation has increased rapidly since last few years. In addition, the government support for research & development for osteoarthritis treatment will create growth opportunities for the global osteoarthritis treatment market. Some of the players profiled in the study are Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (United States), GlaxoSmithKline PLC (United Kingdom), Bayer AG (Germany), Abbott (United States), Pfizer, Inc. (United States), Eli Lilly (United States), Anika Therapeutics, Inc. (United States) and Novartis AG (Switzerland). According to Market Analyst at AMA, the Global Osteoarthritis Therapeutics market may see a growth rate of 9.05%

On the basis of geography, the market of Osteoarthritis Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Europe region held largest market share in the year 2020. North America on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Drug Type, the sub-segment i.e. Prescription Drugs will boost the Osteoarthritis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Parenteral Route will boost the Osteoarthritis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sales Channel, the sub-segment i.e. Hospital Pharmacies will boost the Osteoarthritis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Anatomy, the sub-segment i.e. Knee Osteoarthritis will boost the Osteoarthritis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Growing Occurrence Of Orthopedic Disorders
  • Adoption Of Pain Killer Medications To Avoid Surgical Procedures
  • Rising Number Of Sports Injuries

Influencing Trend
  • Personalized Medicines For Osteoarthritis

Restraints
  • High Cost Associated With Drugs

Opportunities
  • Growing Population Susceptible To Osteoarthritis
  • Collaborations For Product Development

Challenges
  • Adoption Of Non-Drug Pain Management Therapies


Key Market Developments:


In February 2020, FDA approves GlaxoSmithKline’s product named Voltaren Arthritis Pain for over-the-counter use in the United States. This product was developed to provide temporary relief of arthritis pain in the hand, wrist, elbow, foot, knee in adults (18 years and older).ankle or

The market is fragmented by numerous key players who have the bargaining power high in the global osteoarthritis therapeutics market as the market is dominated by several key players. The intensity of rivalry appears to be high in this market as competitors are numerous and the drugs are undifferentiated.

Target Audience:
New Entrants/Investors, Analysts and Strategic Business Planners, Osteoarthritis Therapeutics Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Osteoarthritis Therapeutics market on the basis of product [] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Osteoarthritis Therapeutics market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Osteoarthritis Therapeutics industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Ferring Pharmaceuticals (Switzerland), Bioventus (United States), Zimmer Biomet Holdings, Inc. (United States), Fidia Farmaceutici s.p.a. (Italy), Pharmed Limited (India), Hanmi Pharm. Co., Ltd. (Korea) and Laboratorio Reig Jofre (Spain).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Osteoarthritis Therapeutics market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Drug Type
  • Prescription Drugs
  • Over-the-Counter Drugs

By Route of Administration
  • Parenteral Route
  • Topical Route
  • Oral Route

By Sales Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Anatomy
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis
  • Shoulder Osteoarthritis
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Occurrence Of Orthopedic Disorders
      • 3.2.2. Adoption Of Pain Killer Medications To Avoid Surgical Procedures
      • 3.2.3. Rising Number Of Sports Injuries
    • 3.3. Market Challenges
      • 3.3.1. Adoption Of Non-Drug Pain Management Therapies
    • 3.4. Market Trends
      • 3.4.1. Personalized Medicines For Osteoarthritis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Osteoarthritis Therapeutics, by Drug Type, Route of Administration, Sales Channel, Anatomy and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Osteoarthritis Therapeutics (Value)
      • 5.2.1. Global Osteoarthritis Therapeutics by: Drug Type (Value)
        • 5.2.1.1. Prescription Drugs
        • 5.2.1.2. Over-the-Counter Drugs
      • 5.2.2. Global Osteoarthritis Therapeutics by: Route of Administration (Value)
        • 5.2.2.1. Parenteral Route
        • 5.2.2.2. Topical Route
        • 5.2.2.3. Oral Route
      • 5.2.3. Global Osteoarthritis Therapeutics by: Sales Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Osteoarthritis Therapeutics by: Anatomy (Value)
        • 5.2.4.1. Knee Osteoarthritis
        • 5.2.4.2. Hip Osteoarthritis
        • 5.2.4.3. Hand Osteoarthritis
        • 5.2.4.4. Small Joint Osteoarthritis
        • 5.2.4.5. Shoulder Osteoarthritis
        • 5.2.4.6. Other
      • 5.2.5. Global Osteoarthritis Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Osteoarthritis Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Horizon Therapeutics PLC (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Anika Therapeutics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Osteoarthritis Therapeutics Sale, by Drug Type, Route of Administration, Sales Channel, Anatomy and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Osteoarthritis Therapeutics (Value)
      • 7.2.1. Global Osteoarthritis Therapeutics by: Drug Type (Value)
        • 7.2.1.1. Prescription Drugs
        • 7.2.1.2. Over-the-Counter Drugs
      • 7.2.2. Global Osteoarthritis Therapeutics by: Route of Administration (Value)
        • 7.2.2.1. Parenteral Route
        • 7.2.2.2. Topical Route
        • 7.2.2.3. Oral Route
      • 7.2.3. Global Osteoarthritis Therapeutics by: Sales Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Osteoarthritis Therapeutics by: Anatomy (Value)
        • 7.2.4.1. Knee Osteoarthritis
        • 7.2.4.2. Hip Osteoarthritis
        • 7.2.4.3. Hand Osteoarthritis
        • 7.2.4.4. Small Joint Osteoarthritis
        • 7.2.4.5. Shoulder Osteoarthritis
        • 7.2.4.6. Other
      • 7.2.5. Global Osteoarthritis Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Osteoarthritis Therapeutics: by Drug Type(USD Million)
  • Table 2. Osteoarthritis Therapeutics Prescription Drugs , by Region USD Million (2015-2020)
  • Table 3. Osteoarthritis Therapeutics Over-the-Counter Drugs , by Region USD Million (2015-2020)
  • Table 4. Osteoarthritis Therapeutics: by Route of Administration(USD Million)
  • Table 5. Osteoarthritis Therapeutics Parenteral Route , by Region USD Million (2015-2020)
  • Table 6. Osteoarthritis Therapeutics Topical Route , by Region USD Million (2015-2020)
  • Table 7. Osteoarthritis Therapeutics Oral Route , by Region USD Million (2015-2020)
  • Table 8. Osteoarthritis Therapeutics: by Sales Channel(USD Million)
  • Table 9. Osteoarthritis Therapeutics Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 10. Osteoarthritis Therapeutics Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Osteoarthritis Therapeutics Online Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Osteoarthritis Therapeutics: by Anatomy(USD Million)
  • Table 13. Osteoarthritis Therapeutics Knee Osteoarthritis , by Region USD Million (2015-2020)
  • Table 14. Osteoarthritis Therapeutics Hip Osteoarthritis , by Region USD Million (2015-2020)
  • Table 15. Osteoarthritis Therapeutics Hand Osteoarthritis , by Region USD Million (2015-2020)
  • Table 16. Osteoarthritis Therapeutics Small Joint Osteoarthritis , by Region USD Million (2015-2020)
  • Table 17. Osteoarthritis Therapeutics Shoulder Osteoarthritis , by Region USD Million (2015-2020)
  • Table 18. Osteoarthritis Therapeutics Other , by Region USD Million (2015-2020)
  • Table 19. South America Osteoarthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 20. South America Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 21. South America Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 22. South America Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 23. South America Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 24. Brazil Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 25. Brazil Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 26. Brazil Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 27. Brazil Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 28. Argentina Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 29. Argentina Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 30. Argentina Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 31. Argentina Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 32. Rest of South America Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 33. Rest of South America Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 34. Rest of South America Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 35. Rest of South America Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 36. Asia Pacific Osteoarthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 38. Asia Pacific Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 39. Asia Pacific Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 40. Asia Pacific Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 41. China Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 42. China Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 43. China Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 44. China Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 45. Japan Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 46. Japan Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 47. Japan Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 48. Japan Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 49. India Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 50. India Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 51. India Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 52. India Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 53. South Korea Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 54. South Korea Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 55. South Korea Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 56. South Korea Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 57. Taiwan Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 58. Taiwan Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 59. Taiwan Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 60. Taiwan Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 61. Australia Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 62. Australia Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 63. Australia Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 64. Australia Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 69. Europe Osteoarthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 70. Europe Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 71. Europe Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 72. Europe Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 73. Europe Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 74. Germany Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 75. Germany Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 76. Germany Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 77. Germany Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 78. France Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 79. France Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 80. France Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 81. France Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 82. Italy Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 83. Italy Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 84. Italy Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 85. Italy Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 86. United Kingdom Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 87. United Kingdom Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 88. United Kingdom Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 89. United Kingdom Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 90. Netherlands Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 91. Netherlands Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 92. Netherlands Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 93. Netherlands Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 94. Rest of Europe Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 95. Rest of Europe Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 96. Rest of Europe Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 97. Rest of Europe Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 98. MEA Osteoarthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 99. MEA Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 100. MEA Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 101. MEA Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 102. MEA Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 103. Middle East Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 104. Middle East Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 105. Middle East Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 106. Middle East Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 107. Africa Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 108. Africa Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 109. Africa Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 110. Africa Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 111. North America Osteoarthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 112. North America Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 113. North America Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 114. North America Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 115. North America Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 116. United States Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 117. United States Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 118. United States Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 119. United States Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 120. Canada Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 121. Canada Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 122. Canada Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 123. Canada Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 124. Mexico Osteoarthritis Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 125. Mexico Osteoarthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 126. Mexico Osteoarthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 127. Mexico Osteoarthritis Therapeutics, by Anatomy USD Million (2015-2020)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Osteoarthritis Therapeutics: by Drug Type(USD Million)
  • Table 139. Osteoarthritis Therapeutics Prescription Drugs , by Region USD Million (2021-2026)
  • Table 140. Osteoarthritis Therapeutics Over-the-Counter Drugs , by Region USD Million (2021-2026)
  • Table 141. Osteoarthritis Therapeutics: by Route of Administration(USD Million)
  • Table 142. Osteoarthritis Therapeutics Parenteral Route , by Region USD Million (2021-2026)
  • Table 143. Osteoarthritis Therapeutics Topical Route , by Region USD Million (2021-2026)
  • Table 144. Osteoarthritis Therapeutics Oral Route , by Region USD Million (2021-2026)
  • Table 145. Osteoarthritis Therapeutics: by Sales Channel(USD Million)
  • Table 146. Osteoarthritis Therapeutics Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 147. Osteoarthritis Therapeutics Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 148. Osteoarthritis Therapeutics Online Pharmacies , by Region USD Million (2021-2026)
  • Table 149. Osteoarthritis Therapeutics: by Anatomy(USD Million)
  • Table 150. Osteoarthritis Therapeutics Knee Osteoarthritis , by Region USD Million (2021-2026)
  • Table 151. Osteoarthritis Therapeutics Hip Osteoarthritis , by Region USD Million (2021-2026)
  • Table 152. Osteoarthritis Therapeutics Hand Osteoarthritis , by Region USD Million (2021-2026)
  • Table 153. Osteoarthritis Therapeutics Small Joint Osteoarthritis , by Region USD Million (2021-2026)
  • Table 154. Osteoarthritis Therapeutics Shoulder Osteoarthritis , by Region USD Million (2021-2026)
  • Table 155. Osteoarthritis Therapeutics Other , by Region USD Million (2021-2026)
  • Table 156. South America Osteoarthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 157. South America Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 158. South America Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 159. South America Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 160. South America Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 161. Brazil Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 162. Brazil Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 163. Brazil Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 164. Brazil Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 165. Argentina Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 166. Argentina Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 167. Argentina Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 168. Argentina Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 169. Rest of South America Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 170. Rest of South America Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 171. Rest of South America Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 172. Rest of South America Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 173. Asia Pacific Osteoarthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 174. Asia Pacific Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 175. Asia Pacific Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 176. Asia Pacific Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 177. Asia Pacific Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 178. China Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 179. China Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 180. China Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 181. China Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 182. Japan Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 183. Japan Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 184. Japan Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 185. Japan Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 186. India Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 187. India Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 188. India Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 189. India Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 190. South Korea Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 191. South Korea Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 192. South Korea Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 193. South Korea Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 194. Taiwan Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 195. Taiwan Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 196. Taiwan Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 197. Taiwan Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 198. Australia Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 199. Australia Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 200. Australia Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 201. Australia Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 206. Europe Osteoarthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 207. Europe Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 208. Europe Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 209. Europe Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 210. Europe Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 211. Germany Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 212. Germany Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 213. Germany Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 214. Germany Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 215. France Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 216. France Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 217. France Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 218. France Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 219. Italy Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 220. Italy Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 221. Italy Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 222. Italy Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 223. United Kingdom Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 224. United Kingdom Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 225. United Kingdom Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 226. United Kingdom Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 227. Netherlands Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 228. Netherlands Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 229. Netherlands Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 230. Netherlands Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 231. Rest of Europe Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 232. Rest of Europe Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 233. Rest of Europe Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 234. Rest of Europe Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 235. MEA Osteoarthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 236. MEA Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 237. MEA Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 238. MEA Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 239. MEA Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 240. Middle East Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 241. Middle East Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 242. Middle East Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 243. Middle East Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 244. Africa Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 245. Africa Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 246. Africa Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 247. Africa Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 248. North America Osteoarthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 249. North America Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 250. North America Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 251. North America Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 252. North America Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 253. United States Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 254. United States Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 255. United States Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 256. United States Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 257. Canada Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 258. Canada Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 259. Canada Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 260. Canada Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 261. Mexico Osteoarthritis Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 262. Mexico Osteoarthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 263. Mexico Osteoarthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 264. Mexico Osteoarthritis Therapeutics, by Anatomy USD Million (2021-2026)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Osteoarthritis Therapeutics: by Drug Type USD Million (2015-2020)
  • Figure 5. Global Osteoarthritis Therapeutics: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Osteoarthritis Therapeutics: by Sales Channel USD Million (2015-2020)
  • Figure 7. Global Osteoarthritis Therapeutics: by Anatomy USD Million (2015-2020)
  • Figure 8. South America Osteoarthritis Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Osteoarthritis Therapeutics Share (%), by Country
  • Figure 10. Europe Osteoarthritis Therapeutics Share (%), by Country
  • Figure 11. MEA Osteoarthritis Therapeutics Share (%), by Country
  • Figure 12. North America Osteoarthritis Therapeutics Share (%), by Country
  • Figure 13. Global Osteoarthritis Therapeutics share by Players 2020 (%)
  • Figure 14. Global Osteoarthritis Therapeutics share by Players (Top 3) 2020(%)
  • Figure 15. Global Osteoarthritis Therapeutics share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 18. Sanofi (France) Revenue: by Geography 2020
  • Figure 19. Horizon Therapeutics PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Horizon Therapeutics PLC (Ireland) Revenue: by Geography 2020
  • Figure 21. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 23. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 27. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbott (United States) Revenue: by Geography 2020
  • Figure 29. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly (United States) Revenue: by Geography 2020
  • Figure 33. Anika Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Anika Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 37. Global Osteoarthritis Therapeutics: by Drug Type USD Million (2021-2026)
  • Figure 38. Global Osteoarthritis Therapeutics: by Route of Administration USD Million (2021-2026)
  • Figure 39. Global Osteoarthritis Therapeutics: by Sales Channel USD Million (2021-2026)
  • Figure 40. Global Osteoarthritis Therapeutics: by Anatomy USD Million (2021-2026)
  • Figure 41. South America Osteoarthritis Therapeutics Share (%), by Country
  • Figure 42. Asia Pacific Osteoarthritis Therapeutics Share (%), by Country
  • Figure 43. Europe Osteoarthritis Therapeutics Share (%), by Country
  • Figure 44. MEA Osteoarthritis Therapeutics Share (%), by Country
  • Figure 45. North America Osteoarthritis Therapeutics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Sanofi (France)
  • Horizon Therapeutics PLC (Ireland)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Bayer AG (Germany)
  • Abbott (United States)
  • Pfizer, Inc. (United States)
  • Eli Lilly (United States)
  • Anika Therapeutics, Inc. (United States)
  • Novartis AG (Switzerland)
Additional players considered in the study are as follows:
Ferring Pharmaceuticals (Switzerland) , Bioventus (United States) , Zimmer Biomet Holdings, Inc. (United States) , Fidia Farmaceutici s.p.a. (Italy) , Pharmed Limited (India) , Hanmi Pharm. Co., Ltd. (Korea) , Laboratorio Reig Jofre (Spain)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation